Posts tagged CA4P
Mateon terminates ovarian cancer study, restructures

Mateon Therapeutics (OTCQX:MATN) terminated its Phase 2/3 FOCUS after a third scheduled interim analysis of CA4P in combination with bevacizumab (Avastin) and physician’s choice chemotherapy in patients with platinum-resistant ovarian cancer because of a clear efficacy signal.

Read More
Roth starts Mateon at buy

Roth Capital Markets launched coverage on Mateon Therapeutics (OTCQX:MATN) with a “buy” rating and $2 price target. The stock closed at 77 cents on April 19.

Read More
Mateon collaborates with US Oncology Research

US Oncology Research will participate in Mateon Therapeutics’ (NASDAQ:MATN) FOCUS clinical trial in platinum-resistant ovarian cancer.

In a statement, Dr. William Schwieterman, president and CEO of Mateon, said US Oncology Research is selective about the studies it participates in. “So we are pleased they recognize the importance of developing CA4P for women with platinum-resistant ovarian cancer,” he added.

Read More